Back to search

Peptide record

TPDB05271

cpp HIV-1 Tat (49-57) PTD PTD12 (Tat) TAT TAT (49-57) TAT-aFGF TAT-PTD Antibacterial Anticancer Antifungal Blood-Brain Barrier Cell-penetrating Peptides Toxicity Tumor-homing Peptides standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05271
cpp HIV-1 Tat (49-57) PTD PTD12 (Tat) TAT TAT (49-57) TAT-aFGF TAT-PTD
Antibacterial Anticancer Antifungal Blood-Brain Barrier Cell-penetrating Peptides Toxicity Tumor-homing Peptides
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF CAFPdb dbAMP BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP TumorHoPe2.0
standard
No
A 9-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
RKKRRQRRR
Physicochemical Analysis
C53H106N30O11
ANDCEGHILMFPSTWYV
R
1339.62
13.10
8
0
0
+8
7.42
-4.256
0.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
0
0.00
1
Residue Composition
number
0
A
6
R
0
N
0
D
0
C
0
E
1
Q
0
G
0
H
0
I
0
L
2
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 6 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 0 L: 0 K: 2 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C53H106N30O11
1339.62
13.10
+8
7.42
-4.256
Free
L
Cationic
Linear
Linear
Free
Anticancer
HIV-Tat (49-57)
N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)O N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O N[C@@H](Cc1ccccc1)C(=O)/N=C/C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N1CCC[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCC(=O)N)C(=O)O NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)O N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC/C=N/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
Evidence Records 20 records
Evidence 1 Activity

Activity

~10% Cytotoxicity at 100 µM
Anticancer

Target

Colon Cancer
HCT-116
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

human epithelial lung cell line A549-luc-C8

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Cationic
Protein derived
Nucleic acid (Calcium comlexed siRNA)
In vitro
CCGGGTSCC
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Target

Vero Cells And Hk-2 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
Copper/zinc superoxide dismutase (SOD1)
TAT-SOD1 and R10-SOD1 could efficiently enter cells.
In vitro
CCGGGTSCC
Evidence 4 Activity

Activity

Cell-penetrating Peptides

Target

Pc12 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
Neuroglobin (Ngb)
Cytoplasm, Nuclei, And Neurite Extension
Dose-dependent internalizaion
In vitro
CCGGGTSCC
Evidence 5 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear L Cationic
Protein derived
FITC-labeled
Cytosol, Nucleus and Endosomes
Show considerably lower uptake
In vitro
Evidence 6 Activity

Activity

Cell-penetrating Peptides

Target

Human Sperm Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
cDNA of cAMP sponge
Cytosol
TAT-cAMP sponge transduced into human sperm.
In vitro and in vivo
CTTCGGGGGTSCCGGGCCCCCSSSCC
Evidence 7 Activity

Activity

Cell-penetrating Peptides

Target

T-Rex-293 Cells, Human Embryonic Kidney Cells, Shrna-C3 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
NADH dehydrogenase (ubiquinone) Fe-S protein 8 (NDUFS8)
Mitochondria
Most TAT-NDUFS8 and NDUFS8-TAT l found to be within T-REx-293 cells whereas no NDUFS8 signal without TAT
In vitro
CCCCCCSSSTTCSCCCCSCCCCCBTTBCCCCCC
Evidence 8 Activity

Activity

Cell-penetrating Peptides

Target

S. Aureus Infected Mac-T Or Hbmec Cell Lines , Ex Vivo Calvaria (Skull Cap)

Assay & Model

Femur injury model (Wistar rats (5 to 6 wks of age))
Femur injury model (Wistar rats (5 to 6 wks of age))

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
Lysostaphin and LysK
In vitro and in vivo
CTTTSCCCCHHHHHTGGGGTC
Evidence 9 Activity

Activity

Cell-penetrating Peptides

Target

Human Peritoneal Mesothelial Cells (Hpmcs)

Assay & Model

Male Sprague-Dawley rats (200-250 g) , Female 5 week‐age Balb/C nude mice
Male Sprague-Dawley rats (200-250 g) , Female 5 week‐age Balb/C nude mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
Bone morphogenetic protein‐7 (BMP‐7)
In vitro and in vivo
CCGGGTSCC
Evidence 10 Activity

Activity

Cell-penetrating Peptides

Target

Primary Human CHOndrocytes Explants Of Kellgren-Lawrence Grade Iv Oa Cartilag

Assay & Model

Luciferase reporter mice
Luciferase reporter mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
siRNA and Cre recombinase protein
Cytosol
TAT-PTD increased uptake and partitioning of a fluorescent marker TAMRA.
In vitro and in vivo
CCTTSSCCCCC
Evidence 11 Activity

Activity

Cell-penetrating Peptides

Target

U2Os Cell

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
Myb(397-415) to C terminal via GC linker
Enhanced permeability
In vitro
CCGGGTSCC
Evidence 12 Activity

Activity

Cell-penetrating Peptides

Target

H9C2 Cells

Assay & Model

Seven-week-old C57BL/6N mice
Seven-week-old C57BL/6N mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear L
Synthetic
Cy5 tag CCI Nanoparticels (SCIO-ICG-CRT-CPPs NPs)
CCI NPs displayed a large number of stained myocardial cells, showing enhanced uptake through CPPs and CRT modification. Also , the fluorescent intensities of CCI NPs were significantly enhanced, and those of CCI NPs were 2.96-fold that of CON NPs in the mice model.
Endocytosis
In vitro and in vivo
Evidence 13 Activity

Activity

Cell-penetrating Peptides

Target

Hek293 Cells, Rat Cardiomyocytes

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
Cargo(1–9): IEKELAQQY , Cargo(8–18): QYQNADAITLE, Cargo(1–11): IEKELAQQYQN
Cytosol
TAT had no significant effect on Ca2+ uptake.
In vitro
CCCSSCC
Evidence 14 Activity

Activity

Cell-penetrating Peptides

Target

HCT-116 Cells

Assay & Model

HCT-116 cell-derived tumor bearing male BALB/c nude mice model
HCT-116 cell-derived tumor bearing male BALB/c nude mice model

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
Gold nanoparticles and YW3-56 (356)
Cytosol and Nucleus
The bright blue fluorescence was observed in 356-AuNPs and 356-TAT-AuNPs group, these figures indicated that 356 TAT-AuNPs entered HCT-116 cells effectively. The amounts of Au treated with 356-TAT-AuNPs were 3.1-fold higher than the 356-AuNPs treated group after incubation with 24 h.
In vitro and in vivo
CCTTSSCCCCC
Evidence 15 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
EGFP
Cytoplasm and nucleus
Rapid intracellular uptake of the fusion protein (full-length TOE1-EGFP) but not of the control EGFP alone.
In vitro
CCCBSCSSSCCBSSSSSSSSTTCCCSSBTTBSSCTTCC
Evidence 16 Activity

Activity

Cell-penetrating Peptides

Assay & Model

Male Sprague-Dawley rats (300–350 g) and male BALB/c mice (18–22 g)
Male Sprague-Dawley rats (300–350 g) and male BALB/c mice (18–22 g)

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
Acidic fibroblast growth factor (aFGF)
aFGF alone weakly crossed the epidermis and accumulated in hair follicles, whereas higher levels of fluorescence were detected in or around cell nuclei in the epidermis from TAT-aFGF treated mice
In vivo
CCSCGGGTTCCSCCCSSSCC
Evidence 17 Activity

Activity

Cell-penetrating Peptides

Target

Hek-293T Cells, HeLa Cells And CHO-K1 Cells

Assay & Model

Mice
Mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
rTRPV1 C-terminal fragments 715–725 (CPI) and 736–749 (CPII)
In vitro and in vivo
CCSCSCHHHHHHHHHCC
Evidence 18 Activity

Activity

Cell-penetrating Peptides

Target

PC3 cells

Assay & Model

Female BALB/c mice (20 and 25 g)
Female BALB/c mice (20 and 25 g)

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
Nanoparticles (LPNs) loaded with Docetaxel (DTX) and plasmid DNA
In vitro and in vivo
CCCSSSTTCCCTTTTC
Evidence 19 Activity

Activity

Cell-penetrating Peptides

Target

MCF7 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear L
Protein derived
HF488 labelled PNAs with 2-aminopyridine (M)
Cytoplasm and nucleoli
Strong fluorescence of PNA-Tat and PNA-R8 than PNA-MK3
In vitro
Evidence 20 Activity

Activity

Tumor-homing Peptides

Target

Penetrating

Source & Reference

TumorHoPe2.0
TumorHoPe2
The use of tail-anchored protein chimeras to enhance liposomal cargo delivery
2019
Abdelrehim A et al. PLoS One.2019 Feb 22 14(2):e0212701

Other

Source Activity Label Source Definition
Tumor-homing Peptides
TumorHoPe2.0 experimentally validated tumor-homing peptide annotation.
HeLa M and BeWo
Synthetic
Cytochrome b5 (Cytb5)
Cell penetrating peptide
Additional Detail Fields 3 fields
Cytochrome b5 (Cytb5)
CCGGGTSCC CTTCGGGGGTSCCGGGCCCCCSSSCC CCCCCCSSSTTCSCCCCSCCCCCBTTBCCCCCC CTTTSCCCCHHHHHTGGGGTC CCTTSSCCCCC CCCSSCC CCCBSCSSSCCBSSSSSSSSTTCCCSSBTTBSSCTTCC CCSCGGGTTCCSCCCSSSCC CCSCSCHHHHHHHHHCC CCCSSSTTCCCTTTTC
HeLa M and BeWo